Principal Financial Group Inc. decreased its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 7.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 202,017 shares of the company's stock after selling 16,155 shares during the period. Principal Financial Group Inc. owned approximately 0.41% of Amphastar Pharmaceuticals worth $9,804,000 as of its most recent SEC filing.
Other large investors have also recently bought and sold shares of the company. GAMMA Investing LLC grew its stake in shares of Amphastar Pharmaceuticals by 70.0% in the 3rd quarter. GAMMA Investing LLC now owns 663 shares of the company's stock worth $32,000 after purchasing an additional 273 shares during the last quarter. Innealta Capital LLC acquired a new position in shares of Amphastar Pharmaceuticals in the 2nd quarter worth approximately $55,000. Blue Trust Inc. grew its stake in shares of Amphastar Pharmaceuticals by 23.9% in the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company's stock worth $70,000 after purchasing an additional 309 shares during the last quarter. Asset Management One Co. Ltd. acquired a new position in shares of Amphastar Pharmaceuticals in the 3rd quarter worth approximately $78,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Amphastar Pharmaceuticals by 20.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company's stock worth $85,000 after purchasing an additional 301 shares during the last quarter. Institutional investors and hedge funds own 65.09% of the company's stock.
Amphastar Pharmaceuticals Trading Down 1.2 %
Shares of Amphastar Pharmaceuticals stock traded down $0.54 during trading on Tuesday, hitting $43.62. The stock had a trading volume of 432,584 shares, compared to its average volume of 397,170. The stock has a 50 day simple moving average of $48.39 and a 200 day simple moving average of $44.41. The company has a market capitalization of $2.10 billion, a PE ratio of 14.54, a P/E/G ratio of 0.89 and a beta of 0.82. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. Amphastar Pharmaceuticals, Inc. has a 1 year low of $36.56 and a 1 year high of $65.92.
Analyst Upgrades and Downgrades
AMPH has been the topic of several recent research reports. StockNews.com cut shares of Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, November 1st. Needham & Company LLC reaffirmed a "hold" rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. Finally, Piper Sandler dropped their target price on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an "overweight" rating on the stock in a research report on Thursday, August 8th.
Get Our Latest Stock Report on AMPH
Insider Buying and Selling
In related news, EVP Yakob Liawatidewi sold 5,214 shares of the firm's stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total transaction of $271,388.70. Following the completion of the sale, the executive vice president now directly owns 74,938 shares in the company, valued at approximately $3,900,522.90. This trade represents a 6.51 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Rong Zhou sold 4,000 shares of the firm's stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $48.35, for a total transaction of $193,400.00. Following the sale, the executive vice president now owns 118,388 shares of the company's stock, valued at approximately $5,724,059.80. This represents a 3.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 31,533 shares of company stock worth $1,571,652. 27.10% of the stock is owned by company insiders.
About Amphastar Pharmaceuticals
(
Free Report)
Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.
See Also
Before you consider Amphastar Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amphastar Pharmaceuticals wasn't on the list.
While Amphastar Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
